What do systematic reviews say?

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid)

The review found no eligible studies for this question.

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid)

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) showed no clear difference in menstrual blood loss (alkaline hematin method) compared with placebo or active comparators (paracetamol, tranexamic acid); GRADE not reported.

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  MD 14.11
  Studies not reported
  GRADE not reported
• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  MD 0.3
  Studies not reported
  GRADE not reported

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid)

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) showed no clear difference in duration of bleeding (menstrual diary) compared with placebo or active comparators (paracetamol, tranexamic acid); GRADE not reported.

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  MD 0.2
  Studies not reported
  GRADE not reported

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid)

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 participants
  GRADE not reported

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid)

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  0 participants
  GRADE not reported

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid)

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  0 participants
  GRADE not reported

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid)

The review found no eligible studies for this question.

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid)

The review found no eligible studies for this question.

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid)

The review found no eligible studies for this question.

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Interventions (ibuprofen, tolfenamic acid, aspirin, tranexamic acid) vs placebo or active comparators (paracetamol, tranexamic acid)

The review found no eligible studies for this question.

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention vs control

• Methods to decrease blood loss and transfusion requirements for liver transplantation 2011 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 65 participants
  Very low

Intervention vs control

• Methods to decrease blood loss and transfusion requirements for liver transplantation 2011 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 71 participants
  Very low

Intervention vs control

• Methods to decrease blood loss and transfusion requirements for liver transplantation 2011 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 159 participants
  Very low
• Methods to decrease blood loss and transfusion requirements for liver transplantation 2011 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 198 participants
  Very low

Intervention vs control

It is very uncertain whether intervention changes 60‐day mortality ‐ Tranexamic acid versus control compared with control (very low certainty).

• Methods to decrease blood loss and transfusion requirements for liver transplantation 2011 · Cochrane Headline outcomes only
  RR 0.55 [0.17, 1.76]
  3 studies · 139 participants
  Very low

Intervention vs control

It is very uncertain whether intervention changes 60‐day mortality ‐ Tranexamic acid versus aprotinin compared with control (very low certainty).

• Methods to decrease blood loss and transfusion requirements for liver transplantation 2011 · Cochrane Headline outcomes only
  RR 4.12 [0.71, 23.76]
  2 studies · 178 participants
  Very low

Intervention vs control

It is very uncertain whether intervention changes retransplantation ‐ Tranexamic acid versus control compared with control (very low certainty).

• Methods to decrease blood loss and transfusion requirements for liver transplantation 2011 · Cochrane Headline outcomes only
  RR 0.79 [0.18, 3.48]
  2 studies · 77 participants
  Very low

Intervention vs control

It is very uncertain whether intervention changes thromboembolic episodes ‐ Tranexamic acid versus control compared with control (very low certainty).

• Methods to decrease blood loss and transfusion requirements for liver transplantation 2011 · Cochrane Headline outcomes only
  RR 2.2 [0.38, 12.64]
  5 studies · 179 participants
  Very low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

The review found no eligible studies for this question.

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 38 participants
  Very low

Interventions (vitamin B1, mefenamic acid, tranexamic acid) vs placebo or active comparators (desmopressin, sodium diclofenac, flavonoids)

It is very uncertain whether interventions (vitamin B1, mefenamic acid, tranexamic acid) changes side effects: gastrointestinal disturbances (diarrhoea, lower… compared with placebo or active comparators (desmopressin, sodium diclofenac,… (very low certainty).

• Interventions to prevent or treat heavy menstrual bleeding or pain associated with intrauterine‐device use 2022 · Cochrane Headline outcomes only
  OR 4.69 [1.2, 18.44]
  1 study · 38 participants
  Very low